10-K: Village Farms International Reports 2023 Financial Results, Navigates Market Challenges

Village Farms International's 2023 annual report reveals a complex financial landscape with strategic shifts in its cannabis and produce segments.

Summary

• Village Farms International experienced a decrease in sales by 3% to $285.6 million in 2023, compared to $293.6 million in 2022.
• The company's gross margin significantly improved by 80% to $49.4 million in 2023, up from $27.5 million in 2022.
• Selling, general, and administrative expenses decreased by 9% to $65.5 million in 2023.
• The company reported a net loss of $31.8 million in 2023, a significant improvement from the $101.1 million loss in 2022.
• Adjusted EBITDA for 2023 was $7.6 million, a substantial increase from the negative $34.6 million in 2022.
• The Canadian cannabis segment saw a 4% increase in sales, while the U.S. cannabis segment experienced a 13% decrease.
• The produce segment's sales decreased by 6%, but gross margin improved significantly.
• The company identified a material weakness in internal controls related to the calculation of goodwill and intangible assets.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive improvements in profitability and strategic initiatives, but also highlights challenges in sales and internal controls. The sentiment is neutral to slightly negative due to the identified material weakness and the need for additional financing.

Positives

• Significant improvement in gross margin and adjusted EBITDA.
• Reduced net loss compared to the previous year.
• Strong market position maintained in the Canadian cannabis market.
• Strategic expansion into international cannabis markets.
• Launch of new brands and products in the cannabis segment.
• Re-purposing of a facility to increase tomato production.

Negatives

• Overall sales decreased by 3% year-over-year.
• U.S. cannabis segment experienced a 13% decrease in sales.
• Produce segment sales decreased by 6%.
• A material weakness in internal controls over financial reporting was identified.

Risks

• The company may be unable to regain profitability.
• The company is dependent on the success of its Canadian cannabis business.
• The company faces risks inherent in an agricultural business.
• The legal cannabis and hemp-derived CBD industries are relatively new and may not grow as anticipated.
• The company faces significant competition in the cannabis industry.
• The company is subject to restrictive covenants under its credit facilities.
• The company may need additional financing to further develop its business.
• The company's common shares may be delisted from the Nasdaq Capital Market if it does not regain compliance with the minimum bid price requirements by April 15, 2024.

Future Outlook

The company expects international expansion to enhance profitability and is pursuing opportunities to expand sales, products, and footprint in Canada and internationally. The company also expects the Delta RNG facility to contribute incremental cash flow and profitability.

Management Comments

• Management intends to time the expansion and completion of the east half of the Delta 2 facility when market demand is sufficient to absorb supply profitability.
• Management believes that Pure Sunfarms is the leading low-cost, high-quality producer in the Canadian market.
• Management believes that BHB is uniquely positioned to immediately capitalize on the opportunity if the FDA regulates CBD.

Industry Context

The report highlights the competitive nature of the cannabis and produce industries, with price compression and consolidation affecting market dynamics. The company is adapting to these changes by focusing on low-cost production, branding, and strategic partnerships.

Comparison to Industry Standards

• Pure Sunfarms is positioned as one of the lowest-cost greenhouse producers in the Canadian cannabis market, which is a key competitive advantage compared to other LPs.
• Rose LifeScience is a leading third-party cannabis products commercialization expert in the Province of Quebec, which is a unique position compared to other LPs.
• Balanced Health Botanicals is one of the leading CBD and other cannabinoid brands and e-commerce platforms in the United States, which is a strong position compared to other CBD companies.
• The company's produce business is one of the largest and longest-operating vertically integrated greenhouse growers in North America, which is a strong position compared to other produce companies.

Related Party Transactions

• The Company leases its Rose office building from a company employee who also owns a minority interest in Rose.
• One of the Company's employees is related to a member of the Company's executive management team and received approximately $ 118 , $ 115 and $ 114 in salary and benefits during the years ended December 31, 2023, 2022 and 2021 , respectively.

Stakeholder Impact

• Shareholders may be concerned about the identified material weakness in internal controls and the potential for share price volatility.
• Employees may be affected by potential changes in operations and cost-cutting measures.
• Customers may benefit from the company's focus on quality and innovation.
• Suppliers may be affected by changes in the company's supply chain and purchasing decisions.
• Creditors may be concerned about the company's debt levels and ability to meet its financial obligations.

Next Steps

• The company will continue to pursue operational efficiencies.
• The company will continue to evaluate and pursue profitable international expansion opportunities.
• The company will continue to pursue future opportunities to expand sales, products and footprint in Canada and internationally.
• The company will continue to remediate the material weakness in internal controls over financial reporting.
• The company will continue to evaluate and pursue profitable international expansion opportunities in such markets.

Key Dates

Keywords

cannabis, produce, CBD, greenhouse, financial results, EBITDA, market share, international expansion, internal controls, revenue